Women with early breast cancer to be tested for trastuzumab treatment

doi:10.1136/bmj.331.7521.864

BMJ 2005;331:864 (15 October), doi:10.1136/bmj.331.7521.864

News roundup

Women with early breast cancer to be tested for trastuzumab treatment

London Susan Mayor

All women in England with early stage breast cancer are to be tested to see if they could benefit from trastuzumab (Herceptin), and approval for use of the drug by the NHS will be fast tracked once it has been licensed. The government announced these measures last week after a campaign by women demanding prompt access to this treatment.

Health Secretary Patricia Hewitt announced that all women diagnosed with early stage breast cancer would be tested for suitability for treatment with trastuzumab. The drug is a monoclonal antibody that binds to the HER2 receptor, a cell surface protein that can be tested for and which is overexpressed in about a fifth of breast cancers. The drug is currently licensed for use only in women with advanced breast cancer who test positive for HER2, but studies reported to the American Society of Clinical Oncology in May this year . . . [Full text of this article]

Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to StumbleUpon StumbleUpon Add to Technorati Technorati What's this?

Relevant Articles

Trastuzumab for early breast cancer raises important issues: Edward C F Wilson
BMJ 2005 331: 1023. [Extract] [Full Text]

Keep politics out of it: Fiona Godlee
BMJ 2005 331: 0. [Extract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

Herceptin for early breast cancer: Edward CF Wilson
bmj.com, 17 Oct 2005 [Full text]
More imponderables: Anne J Ward
bmj.com, 31 Oct 2005 [Full text]